































## เอกสารอ้างอิง

1. Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non-alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. *BMC Pediatr* 2013; 13: 40.
2. de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, et al. Recommendations for the management of tyrosinaemia type 1. *Orphanet J Rare Dis* 2013; 8: 8.
3. Russo PA<sup>1</sup>, Mitchell GA, Tanguay RM. Tyrosinemia: a review. *Pediatr Dev Pathol* 2001; 4: 212-21.
4. Mayorandan S<sup>1</sup>, Meyer U<sup>2</sup>, Gokcay G<sup>3</sup>, Segarra NG<sup>4</sup>, de Gaulny H<sup>5</sup>, van Spronsen F<sup>6</sup>, et al. Cross-sectional study of 168 patients with hepatocatal tyrosinemia and implications for clinical practice. *Orphanet J Rare Dis* 2014; 9: 10.
5. Nakamura K<sup>1</sup>, Matsumoto S, Mitsubuchi M, Endo F. Diagnosis and treatment of hereditary tyrosinemia in Japan. *Pediatr Int.* 2015; 57: 37-40.

bthai gastro.org